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Background: A six-item version (PANSS-6: P1=Delusions, P2=Conceptual 
disorganization, P3=Hallucinations, N1=Blunted Affect, N4=Social with-
drawal, N6=Lack of spontaneity/flow of conversation) of the 30-item 
Positive and Negative Syndrome Scale (PANSS-30) has shown promise in 
the measurement of symptom severity in acutely exacerbated- and chronic 
schizophrenia, but its validity in treatment-resistant schizophrenia remains 
unknown. Therefore, we tested the validity and sensitivity of PANSS-6 
based on data from the clozapine phase of the Clinical Antipsychotic Trials 
of Intervention Effectiveness (CATIE) study.
Methods: I) The scalability of PANSS-6 and PANSS-30 (i.e., whether all 
items provide unique information regarding syndrome severity) was tested 
by means of item response theory analysis ad modum Rasch; II) The cor-
relation between PANSS-6 and PANSS-30 total scores was investigated by 
means of Spearman correlation analysis; III) The accuracy of PANSS-6 
in identifying symptom remission was tested by comparing remission on 
PANSS-6 (score of ≤3 on each of the six PANSS-6 items) with remission 
according to the Andreasen criteria (score of ≤3 on the 8 PANSS items 
considered in the Andreasen criteria); and IV) The antipsychotic effect of 
clozapine was compared to that of olanzapine, risperidone and quetiapine 
using the “speed of change” on PANSS-6 and PANSS-30 (change in total 
score per day) as outcomes.
Results: We found that I) only PANSS-6 and not PANSS-30 was scalable; 
II) The correlation between PANSS-6 and PANSS-30 total scores was high 
(Spearman coefficient: 0.85), III) PANSS-6 did accurately classify syn-
drome remission as defined by the Andreasen criteria, and IV) The only 
antipsychotic that resulted in improvement (speed of change significantly 
lower than 0 during the first three months of treatment) was clozapine, both 
when using PANSS-6 (speed of change: -0.072 points/day; 95%CI: -0.121, 
-0.024) and when using PANSS-30 (speed of change: -0.201 points/day; 
95%CI: -0.400, -0.002) as outcome measures.
Discussion: These findings suggest that PANSS-6 validly measures severity, 
remission and antipsychotic efficacy in treatment-resistant schizophrenia.
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Background: Patients with schizophrenia often display three main types 
of symptoms: positive symptoms (e.g. auditory hallucinations or delu-
sions), negative symptoms (e.g. blunted affect, lack or decline in speech, 
social withdrawal) and cognitive symptoms (e.g. impairment of working 
memory and declarative memory). Treatment of positive symptoms with 
available antipsychotics is well established, while therapy options for cogni-
tive and negative symptoms are lacking. Neurobiological studies identified 
an enhanced NRG1-ERBB4 signaling as a risk pathway in schizophrenia. 
Spironolactone was found to function as an inhibitor of the ERBB4 recep-
tor. In Nrg1 type III transgenic mice, spironolactone treatment led to an 
improvement of schizophrenia-like symptoms (Wehr et al. 2017). This is the 
first study to investigate an add-on spironolactone treatment in schizophre-
nia patients for the treatment of cognitive deficits.
Methods: This is a multicenter, randomized, double-blind, parallel 
(3-groups), longitudinal pilot study including 3 x 27 (81) patients with a 
clinically stable schizophrenia. Patients are randomized in three groups: 
one group receives add-on spironolactone 100 mg for three weeks (inter-
vention I), one group receives add-on spironolactone 200  mg for three 
weeks (intervention II) and one group receives add-on placebo for three 
weeks (control group). The primary endpoint is the modification of the 
working memory in dependence to the intervention as investigated with the 
n-back task (0-, 1- and 2-back). Secondary endpoints include: modifica-
tion of other cognitive functions (e.g. declarative memory and attention), 
psychopathology (e.g. PANSS and CDSS), overall level of functioning via 
GAF and severity of disease via CGI, changes in the number of patients 
in remission using the Andreasen Criteria, modifications of the inhibitory 
cortical function in the context of the prepuls paradigm with TMS, evalu-
ating possible dose-differences, spironolactone effects on mRNA levels in 
peripheral blood lymphocytes (PBMC measures). Statistical analysis of the 
primary endpoint will be based on the intention-to-treat (ITT) population 
including all randomised patients using a mixed model ANOVA.
Results: The first patient was recruited in July 2015. Currently 45 patients 
are included in the trial. The overall tolerance of the medication was sat-
isfactory with 48 reported AE (adverse events). In 3 cases, the causality 
of the medication was definite, in 4 cases probable and in 5 cases possible. 
The other cases were probably or definitely not related to the study medica-
tion. SAE (serious adverse events) were not reported. The current state of 
research will be discussed on the conference.
Discussion: This is the first study to describe the effects of an add-on treat-
ment of spironolactone in patients with a clinically stable schizophrenia. 
Also, it is the first study with a direct target of a biochemically disturbed 
signaling pathway in schizophrenia patients with a possibly new treatment 
option in this severe disease.
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Background: Schizophrenia is a severe mental disorder requiring multi-
modal treatment. Monitoring the severity of schizophrenia during treat-
ment is essential to a successful outcome. The most widely used measure of 
the severity of schizophrenia is the 30-item Positive And Negative Syndrome 
Scale (PANSS-30) obtained by the Structured Clinical Interview, SCI-
PANSS, which takes approximately an hour to administer. This is too long 
for routine clinical use. Recently, our group extracted a 6-item scale (PANSS-
6), which has shown promising psychometric properties. The scale consists 
of the following items: P1 - Delusions, P2 - Conceptual disorganization, P3 
- Hallucinatory behavior, N1 - Blunted Affect, N4 - Passive/apathetic social 
withdrawal and N6 - Lack of spontaneity & flow of conversation. For now, 
it remains unknown whether it is possible to obtain sufficient information 
for PANSS-6 rating via a short and focused interview. Recently, our group 
developed an interview, the Simplified Negative and Positive Symptoms 
Interview (SNAPSI), which enables PANSS-6 rating. Field-testing at hos-
pitals in the United States and Denmark has shown that the patient sec-
tion of SNAPSI can be completed in approximately 15–25 minutes by raters 
who are unfamiliar with the interview and involving patients hearing the 
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